HealthEquity (HQY)
(Delayed Data from NSDQ)
$78.91 USD
-1.39 (-1.73%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $78.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$78.91 USD
-1.39 (-1.73%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $78.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Zacks News
Inogen's (INGN) Preliminary Q2 Revenues Dampened by Lower Sales
by Zacks Equity Research
Inogen's (INGN) revenue growth in the second quarter is likely to have been hampered by lower revenues in its business-to-business and direct-to-consumer channels.
Thermo Fisher (TMO) Launches Diomni Enterprise Software
by Zacks Equity Research
Thermo Fisher's (TMO) Diomni Enterprise Software effortlessly connects each individual processing stage to a single, integrated platform.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
CVS Health (CVS) Launches Caremark Cost Saver With a New Pact
by Zacks Equity Research
CVS Health (CVS) is able to dynamically shop for the lowest price on its clients' behalf with the help of Caremark Cost Saver solution.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Illumina's (ILMN) Latest Launch to Boost Genomics Analysis
by Zacks Equity Research
Illumina's (ILMN) DRAGEN v4.2 is expected to improve the identification of genetic disease causes, drug discovery and population genomics.
What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?
by Zacks Equity Research
The recent FDA approvals and growing customer demand for core therapeutic lines is likely to have driven Abbott's (ABT) Q2 performance.
Alcon (ALC) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are bullish about Alcon (ALC) owing to solid demand, strong commercial execution and pricing improvements across the Surgical and Vision Care franchises.
DaVita (DVA) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about DaVita's (DVA) strength in its kidney care.
AngioDynamics (ANGO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AngioDynamics' (ANGO) fiscal fourth quarter's top line is likely to have been driven by strong demand for its products.
Alcon (ALC) Surgical End Market Grows, Vision Care Sales Rise
by Zacks Equity Research
In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.
Here's Why Investors Should Hold Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology's (ALGN) Invisalign portfolio expansion and strategic alliances.
Quest Diagnostics' (DGX) New Pact to Get Home Fertility Test
by Zacks Equity Research
The Proov Confirm home collection kit can be purchased now on Quest Diagnostics' questhealth.com for $29.
3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
HealthEquity (HQY) Down 5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DexCom's (DXCM) G7 CGM System Gets Nod From Health Canada
by Zacks Equity Research
DexCom's (DXCM) G7 CGM System's latest approval by Health Canada is expected to combine simplicity and power, thereby providing a better way to manage diabetes.
LabCorp (LH) Partners With Forge Biologics for Gene Therapies
by Zacks Equity Research
LabCorp's (LH) latest partnership will significantly assist patients gain access to cutting-edge, potentially life-saving medication.
3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
Here's Why You Should Buy Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard growth and raised guidance.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.
Quest Diagnostics (DGX) Presents New Data on Disease Testing
by Zacks Equity Research
Quest Diagnostics (DGX) is dedicated to create cutting-edge laboratory tests to help assess patient risk for dementia and other degenerative diseases.
Here's Why You Should Invest in Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are upbeat about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.
Baxter's (BAX) New Launch to Support Complex Critical Care Needs
by Zacks Equity Research
Baxter's (BAX) Progressa+ bed for the ICU is expected to enhance workflow and reduce strain on nursing resources.